Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy

Journal of Neuro-Oncology

Volumn 101, Issue 1, 2011, Pages 155-159

  Peters, Katherine B ^a   Coyle, Thomas E ^b   Vredenburgh, James J ^a   Desjardins, Annick ^a   Friedman, Henry S ^a   Reardon, David A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Bevacizumab; Brain tumor; Corticosteroid; Striae distensae

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; DEXAMETHASONE; ETOPOSIDE; IRINOTECAN; LIDOCAINE; TEMOZOLOMIDE; XIPAMIDE;

ACNE; ADULT; ARTICLE; BRAIN EDEMA; CANCER GRADING; CANCER MORTALITY; CASE REPORT; CAUSE OF DEATH; CHRONIC DRUG ADMINISTRATION; CONTRAST ENHANCEMENT; CRANIOTOMY; CUSHINGOID SYNDROME; CYTOREDUCTIVE SURGERY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOCAL EPILEPSY; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IATROGENIC DISEASE; LOW DRUG DOSE; MALE; MOON FACE; MULTIPLE CYCLE TREATMENT; MYOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; SKIN BIOPSY; SKIN DISCOLORATION; SKIN INJURY; SKIN ULCER; STRIA; SYSTEMIC THERAPY; TREATMENT DURATION; TUMOR BIOPSY; WOUND DRESSING; WOUND HEALING IMPAIRMENT;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DEXAMETHASONE; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; STRIAE DISTENSAE; ULCER; YOUNG ADULT;

EID: 78651276029     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0239-0     Document Type: Article

References (17)

1. G Singh LP Kumar 2005 Striae distensae Indian J Dermatol Venereol Leprol 71 370 372 10.4103/0378-6323.16800 16394474
2. G Yosipovitch A DeVore A Dawn 2007 Obesity and the skin: skin physiology and skin manifestations of obesity J Am Acad Dermatol 56 901 916 10.1016/j.jaad.2006.12.004 17504714 (quiz 917-920)
3. P Autio A Oikarinen J Melkko J Risteli L Risteli 1994 Systemic glucocorticoids decrease the synthesis of type I and type III collagen in human skin in vivo, whereas isotretinoin treatment has little effect Br J Dermatol 131 660 663 1:STN:280:DyaK2M%2Fpt1Gktg%3D%3D 10.1111/j.1365-2133.1994.tb04978.x 7999597
4. Y Oishi ZW Fu Y Ohnuki H Kato T Noguchi 2002 Molecular basis of the alteration in skin collagen metabolism in response to in vivo dexamethasone treatment: effects on the synthesis of collagen type I and III, collagenase, and tissue inhibitors of metalloproteinases Br J Dermatol 147 859 868 1:CAS:528:DC%2BD38Xps1Krsbs%3D 10.1046/j.1365-2133.2002.04949.x 12410694
5. FN Daly D Schiff 2007 Supportive management of patients with brain tumors Expert Rev Neurother 7 1327 1336 1:CAS:528:DC%2BD2sXhtFOjtrnL 10.1586/14737175.7.10.1327 17939770
6. AA Pruitt 2005 Treatment of medical complications in patients with brain tumors Curr Treat Options Neurol 7 323 336 10.1007/s11940-005-0042-y 15967095
7. HS Friedman MD Prados PY Wen T Mikkelsen D Schiff LE Abrey WK Yung N Paleologos MK Nicholas R Jensen J Vredenburgh J Huang M Zheng T Cloughesy 2009 Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 4733 4740 1:CAS:528:DC%2BD1MXhtlGgtbbM 10.1200/JCO.2008.19.8721 19720927
8. JJ Vredenburgh A Desjardins JE Herndon II JM Dowell DA Reardon JA Quinn JN Rich S Sathornsumetee S Gururangan M Wagner DD Bigner AH Friedman HS Friedman 2007 Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Clin Cancer Res 13 1253 1259 1:CAS:528:DC%2BD2sXhvF2htr8%3D 10.1158/1078-0432.CCR-06-2309 17317837
9. JJ Vredenburgh A Desjardins JE Herndon 2nd J Marcello DA Reardon JA Quinn JN Rich S Sathornsumetee S Gururangan J Sampson M Wagner L Bailey DD Bigner AH Friedman HS Friedman 2007 Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 4722 4729 1:CAS:528:DC%2BD2sXhtlCgsLjF 10.1200/JCO.2007.12.2440 17947719
10. TN Kreisl L Kim K Moore P Duic C Royce I Stroud N Garren M Mackey JA Butman K Camphausen J Park PS Albert HA Fine 2009 Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J Clin Oncol 27 740 745 1:CAS:528:DC%2BD1MXjsVCjs7o%3D 10.1200/JCO.2008.16.3055 19114704
11. N Ferrara KJ Hillan W Novotny 2005 Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy Biochem Biophys Res Commun 333 328 335 1:CAS:528:DC%2BD2MXlsVChtLs%3D 10.1016/j.bbrc.2005.05.132 15961063
12. H Hurwitz S Saini 2006 Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events Semin Oncol 33 S26 S34 1:CAS:528:DC%2BD28Xhtlajt7vM 10.1053/j.seminoncol.2006.08.001 17145522
13. FA Scappaticci L Fehrenbacher T Cartwright JD Hainsworth W Heim J Berlin F Kabbinavar W Novotny S Sarkar H Hurwitz 2005 Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab J Surg Oncol 91 173 180 1:CAS:528:DC%2BD2MXhtVGltrnK 10.1002/jso.20301 16118771
14. RC Cordeiro AM Moraes 2008 Ulceration of striae distensae in a patient with systemic lupus erythematosus J Eur Acad Dermatol Venereol 22 390 392 1:STN:280:DC%2BD1c7ht1Ontg%3D%3D 10.1111/j.1468-3083.2007.02343.x 18269620
15. MG Tonnesen X Feng RA Clark 2000 Angiogenesis in wound healing J Investig Dermatol Symp Proc 5 40 46 1:CAS:528:DC%2BD3MXhtVeltbY%3D 10.1046/j.1087-0024. 2000.00014.x 11147674
16. C Hempen E Weiss CF Hess 2002 Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects? Support Care Cancer 10 322 328 10.1007/s00520-001-0333-0 12029432
17. S Ananthnarayan J Bahng J Roring P Nghiemphu A Lai T Cloughesy WB Pope 2008 Time course of imaging changes of GBM during extended bevacizumab treatment J Neurooncol 88 339 347 10.1007/s11060-008-9573-x 18389177